ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!


Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case. They would like ROS1+ patients who have taking crizotinib to share the following information (no names): Demographic data (e.g., … Continue reading ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!

ROS1+ lung cancer patients: Paid opportunity to share your experience for research


The ROS1ders received the information below directly from the researcher, and agreed to share it in hopes patients with ROS1+ NSCLC would participate.  We receive no compensation of any kind for sharing this information. ————————————- INVITATION TO PARTICIPATE IN RESEARCH STUDY “The Lived-Experience and Needs of Lung Cancer Patients with Driver Mutations” We invite you … Continue reading ROS1+ lung cancer patients: Paid opportunity to share your experience for research

Presentations on ROS1+ Cancer at IASLC #WCLC2018


Members of The ROS1ders will be attending The International Association for the Study of Lung Cancer’s (IASLC) annual World Conference on Lung Cancer (WCLC) in Toronto, Canada, September 23-26, 2018.  The Twitter hashtag for the conference is #WCLC2018. Presentations that will mention ROS1+ cancer are listed below.  The abstract book containing these and other WCLC … Continue reading Presentations on ROS1+ Cancer at IASLC #WCLC2018

The value of oncogene-focused patient-caregiver groups


Thanks to Dr. H. Jack West for the shout-out to our ros1cancer.com website and our page Drugs to Treat ROS1+ Cancer! Time to highlight that we are now in an era when pts w/rare cancers are increasingly likely to know more than docs, even very good ones, about their dzs. This @ros1cancer page on Drugs … Continue reading The value of oncogene-focused patient-caregiver groups

Should we combine TKIs and immunotherapy?


Some researchers think combining immunotherapy and certain targeted therapies called tyrosine kinase inhibitors (TKIs) may be too toxic for patients. This Phase 1/2 study supports that idea. It combined nivolumab and full-dose crizotinib in ALK+ non-small cell lung cancer, and was discontinued for safety reasons when 38% of the first 13 patients developed liver problems … Continue reading Should we combine TKIs and immunotherapy?